Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.8M
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
39.1M
-
Shares change
-
+2.11M
-
Total reported value, excl. options
-
$307M
-
Value change
-
+$16.2M
-
Put/Call ratio
-
3.75
-
Number of buys
-
45
-
Number of sells
-
-24
-
Price
-
$7.85
Significant Holders of Aura Biosciences, Inc. - Common Stock (AURA) as of Q1 2024
86 filings reported holding AURA - Aura Biosciences, Inc. - Common Stock as of Q1 2024.
Aura Biosciences, Inc. - Common Stock (AURA) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.1M shares
of 61.8M outstanding shares and own 63.32% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (6.92M shares), EVENTIDE ASSET MANAGEMENT, LLC (5.8M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.47M shares), CITADEL ADVISORS LLC (3.68M shares), Medicxi Ventures Management (Jersey) Ltd (3.04M shares), BlackRock Inc. (2.44M shares), VANGUARD GROUP INC (1.69M shares), FRANKLIN RESOURCES INC (1.45M shares), Nantahala Capital Management, LLC (1.32M shares), and GOLDMAN SACHS GROUP INC (997K shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.